Cargando…

Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts

Chronic Myeloid Leukemia (CML) is a hematological disorder characterized by the clonal expansion of a hematopoietic stem cell carrying the Philadelphia chromosome that juxtaposes the BCR and ABL1 genes. The ensuing BCR-ABL1 chimeric oncogene is characterized by a breakpoint region that generally inv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Massimino, Michele, Tirrò, Elena, Stella, Stefania, Manzella, Livia, Pennisi, Maria Stella, Romano, Chiara, Vitale, Silvia Rita, Puma, Adriana, Tomarchio, Cristina, Di Gregorio, Sandra, Antolino, Agostino, Di Raimondo, Francesco, Vigneri, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277938/ https://www.ncbi.nlm.nih.gov/pubmed/34276365 http://dx.doi.org/10.3389/fphar.2021.669469

Ejemplares similares

BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors
por: Pennisi, Maria Stella, et al.
Publicado: (2019)

High BCR::ABL1 Expression Defines CD34+ Cells with Significant Alterations in Signal Transduction, Short-Proliferative Potential and Self-Renewal Ability
por: Massimino, Michele, et al.
Publicado: (2023)

Combined Inhibition of Bcl2 and Bcr-Abl1 Exercises Anti-Leukemia Activity but Does Not Eradicate the Primitive Leukemic Cells
por: Massimino, Michele, et al.
Publicado: (2021)

Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia
por: Massimino, Michele, et al.
Publicado: (2018)

Molecular Pathogenesis and Treatment Perspectives for Hypereosinophilia and Hypereosinophilic Syndromes
por: Stella, Stefania, et al.
Publicado: (2021)

Prognostic and Therapeutic Roles of the Insulin Growth Factor System in Glioblastoma
por: Tirrò, Elena, et al.
Publicado: (2021)

Opportunities and Challenges of Liquid Biopsy in Thyroid Cancer
por: Romano, Chiara, et al.
Publicado: (2021)

A Novel System for Semiautomatic Sample Processing in Chronic Myeloid Leukaemia: Increasing Throughput without Impacting on Molecular Monitoring at Time of SARS-CoV-2 Pandemic
por: Stella, Stefania, et al.
Publicado: (2021)

Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients
por: Stella, Stefania, et al.
Publicado: (2022)

New Insights in Thyroid Cancer and p53 Family Proteins
por: Manzella, Livia, et al.
Publicado: (2017)

Activation of the IGF Axis in Thyroid Cancer: Implications for Tumorigenesis and Treatment
por: Manzella, Livia, et al.
Publicado: (2019)

Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice
por: Tirrò, Elena, et al.
Publicado: (2019)

The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy
por: Vigneri, Paolo Giovanni, et al.
Publicado: (2015)

Single-Cell Analysis in the Omics Era: Technologies and Applications in Cancer
por: Massimino, Michele, et al.
Publicado: (2023)

Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib
por: Stella, Stefania, et al.
Publicado: (2019)

Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53
por: Tirrò, Elena, et al.
Publicado: (2019)

Additional Genetic Alterations and Clonal Evolution of MPNs with Double Mutations on the MPL Gene: Two Case Reports
por: Pennisi, Maria Stella, et al.
Publicado: (2023)

Potential Therapeutic Targets for Luminal Androgen Receptor Breast Cancer: What We Know so Far
por: Stella, Stefania, et al.
Publicado: (2023)

Reciprocal t(9;22) ABL/BCR Fusion Proteins: Leukemogenic Potential and Effects on B Cell Commitment
por: Zheng, Xiaomin, et al.
Publicado: (2009)

Glucose-dependent effect of insulin receptor isoforms on tamoxifen antitumor activity in estrogen receptor-positive breast cancer cells
por: Stella, Stefania, et al.
Publicado: (2023)

Flow Cytometric Immunobead Assay for Detection of BCR-ABL1 Fusion Proteins in Chronic Myleoid Leukemia: Comparison with FISH and PCR Techniques
por: Recchia, Anna Grazia, et al.
Publicado: (2015)

Expression of Constitutively Active Raf-1 in the Mitochondria Restores Antiapoptotic and Leukemogenic Potential of a Transformation-deficient BCR/ABL Mutant
por: Salomoni, Paolo, et al.
Publicado: (1998)

Loss of the xeroderma pigmentosum group B protein binding site impairs p210 BCR/ABL1 leukemogenic activity
por: Pannucci, N L, et al.
Publicado: (2013)

BCR-ABL tyrosine kinase inhibitor (TKI)-induced nephropathy: An under-recognized phenomenon
por: Stanchina, Michele, et al.
Publicado: (2020)

Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition
por: Mitchell, Rebecca, et al.
Publicado: (2017)

Migrating to Long-Read Sequencing for Clinical Routine BCR-ABL1 TKI Resistance Mutation Screening
por: Schaal, Wesley, et al.
Publicado: (2022)

The other side of the coin: dissecting molecular mechanisms behind hereditary breast cancer in search of therapeutic opportunities
por: Stella, Stefania, et al.
Publicado: (2021)

The Q-LAMP Method Represents a Valid and Rapid Alternative for the Detection of the BCR-ABL1 Rearrangement in Philadelphia-Positive Leukemias
por: Stella, Stefania, et al.
Publicado: (2019)

Susceptibility Of Ph-Positive All To Tki Therapy Associated With Bcr-Abl Rearrangement Patterns: A Retrospective Analysis
por: Jing, Yu, et al.
Publicado: (2014)

BCR‐ABL exon 7 deletion and novel point mutation in patient with chronic myelogenous leukemia and TKI resistance
por: Mikhailov, Ilya
Publicado: (2018)

BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment‐free remission: A study from the “GRUPPO TRIVENETO LMC”
por: Di Giusto, Sara, et al.
Publicado: (2022)

New Genetic Variation in BCR gene of Major B3a2 Breakpoint BCR-ABL Fusion Gene in Patients with Chronic Myelogenous Leukemia in Yogyakarta, Indonesia
por: Sholikah, Tri Agusti, et al.
Publicado: (2017)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

AKT Inhibitors: New Weapons in the Fight Against Breast Cancer?
por: Martorana, Federica, et al.
Publicado: (2021)

Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia
por: Polillo, Marialuisa, et al.
Publicado: (2015)

Targeting BCR-ABL(+) stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex
por: Chen, Min, et al.
Publicado: (2017)

BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance
por: Parker, W T, et al.
Publicado: (2013)

The P190, P210, and P230 Forms of the BCR/ABL Oncogene Induce a Similar Chronic Myeloid Leukemia–like Syndrome in Mice but Have Different Lymphoid Leukemogenic Activity
por: Li, Shaoguang, et al.
Publicado: (1999)

Genomic BCR-ABL1 breakpoint characterization by a multi-strategy approach for “personalized monitoring” of residual disease in chronic myeloid leukemia patients
por: Cumbo, Cosimo, et al.
Publicado: (2018)

Interplay between Kinase Domain Autophosphorylation and F-Actin Binding Domain in Regulating Imatinib Sensitivity and Nuclear Import of BCR-ABL
por: Preyer, Martin, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_k0vviljvad5neb1vvuki766msg